YC Biotech and Xinxi Community Health Care Group have officially joined forces to expand access to EG BioMed’s DNA methylation cancer marker testing. The collaboration was celebrated with a signing banquet at Lemon Grass Restaurant in Xinzhuang, where both organizations reaffirmed their shared commitment to enhancing early cancer detection through innovative medical technology.
This cutting-edge testing method is recognized for its simplicity, speed, and accuracy, offering a more comfortable experience for individuals undergoing screening. Through this partnership, clinics within the Xinxi Community Health Care Group network will integrate EG BioMed’s DNA methylation testing into their diagnostic services, providing patients with a more advanced approach to cancer detection.
The event unfolded in a warm and engaging atmosphere, with attendees expressing enthusiasm for the potential impact of this collaboration. Conversations during the gathering provided valuable insights that will help refine the integration of this technology into clinical practice.
As a leader in precision medicine, YC Biotech remains dedicated to developing and delivering innovative medical products and services that meet the evolving needs of the healthcare industry. Working with Xinxi Community Health Care Group not only expands YC Biotech’s business reach but also accelerates the adoption of next-generation cancer screening technology in Taiwan.
Xinxi Community Health Care Group, a key provider of medical services in Taiwan, is committed to delivering high-quality healthcare while embracing medical innovation. Their strong support for EG BioMed’s technology underscores their dedication to enhancing diagnostic capabilities and improving patient care.
By working together, YC Biotech and Xinxi Community Health Care Group aim to drive the widespread adoption of EG BioMed’s DNA methylation cancer marker testing, making a meaningful contribution to the continued advancement of healthcare services.